Detection of internal N7-methylguanosine (m7G) RNA modifications by mutational profiling sequencing

Enroth, Christel; Poulsen, Line Dahl; Iversen, Søren; Kirpekar, Finn; Albrechtsen, Anders; Vinther, Jeppe

Published in:
Nucleic Acids Research

DOI:
10.1093/nar/gkz736

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Enroth, C., Poulsen, L. D., Iversen, S., Kirpekar, F., Albrechtsen, A., & Vinther, J. (2019). Detection of internal N7-methylguanosine (m7G) RNA modifications by mutational profiling sequencing. Nucleic Acids Research, 47(20), [e126]. https://doi.org/10.1093/nar/gkz736
Detection of internal N7-methylguanosine (m7G) RNA modifications by mutational profiling sequencing

Christel Enroth1,†, Line Dahl Poulsen1,†, Soren Iversen1, Finn Kirpekar2, Anders Albrechtsen1 and Jeppe Vinther1,†

1Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, DK-2200 Copenhagen N, Denmark and 2Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark

Received October 31, 2018; Revised August 06, 2019; Editorial Decision August 08, 2019; Accepted August 16, 2019

ABSTRACT
Methylation of guanosine on position N7 (m7G) on internal RNA positions has been found in all domains of life and have been implicated in human disease. Here, we present m7G Mutational Profiling sequencing (m7G-MaP-seq), which allows high throughput detection of m7G modifications at nucleotide resolution. In our method, m7G modified positions are converted to abasic sites by reduction with sodium borohydride, directly recorded as cDNA mutations through reverse transcription and sequenced. We detect positions with increased mutation rates in the reduced and control samples taking the possibility of sequencing/alignment error into account and use replicates to calculate statistical significance based on log likelihood ratio tests. We show that m7G-MaP-seq efficiently detects known m7G modifications in rRNA with mutation rates up to 25% and we map a previously uncharacterised evolutionarily conserved RNA modification at position 1581 in Arabidopsis thaliana SSU rRNA. Furthermore, we identify m7G modifications in budding yeast, human and Arabidopsis tRNAs and demonstrate that m7G modification occurs before tRNA splicing. We do not find any evidence for internal m7G modifications being present in other small RNA, such as miRNA, snoRNA and sRNA, including human Let-7e. Likewise, high sequencing depth m7G-MaP-seq analysis of mRNA from E. coli or yeast cells did not identify any internal m7G modifications.

INTRODUCTION
It is becoming increasingly clear that RNA modifications play important roles in many cellular processes and evidence linking the proteins responsible for modification of RNA to the development of human diseases is accumulating (1). This is also true for methylation of guanosine position 7 (m7G), which is present at internal positions in both tRNA and rRNA. In the yeast small ribosomal subunit (SSU) rRNA, position 1575 is m7G modified by the Bud23-Trm112 heterodimer (2,3) and this modification is conserved to human SSU rRNA position 1639 (4,5). Most bacterial ribosomes are also m7G modified, including the Escherichia coli ribosome, which has a m7G modification both on the SSU and the LSU rRNAs (6,7). Likewise, some tRNAs has a conserved m7G modification at position 46, which stabilises the tertiary tRNA fold by improving the geometry of a base triple N13-N22-m7G46 (8,9). The set of tRNAs carrying the m7G modification is only known with some confidence in yeast (10,11) and recently also in mice (12) and humans (13).

The mapping of RNA modifications has been improved by the development of a variety of sequencing based global detection methods, which in some cases has allowed mRNA modifications to be detected (14). The detection of the N1-methyladenosine (m1A) RNA modification is an example of this development. The m1A modification causes stops or misincorporations during reverse transcription. Initially, m1A was detected on a global scale using specific antibodies to immunoprecipitate m1A modified RNA combined with detection of the reverse transcriptase stop events resulting from m1A (15,16). Subsequently, the availability of thermostable group II intron reverse transcriptase fusion proteins (TGIRT) made it possible to increase the proportion of m1A reverse transcriptase read-throughs compared to stops. This allowed m1A immunoprecipitation to be combined with mutational profiling of m1A, thereby increasing the signal to noise ratio and improving m1A detection (17–19). RNA modifications, including m1A, are abundant in tRNA and their interference with reverse transcription makes mapping of tRNA modifications challenging.

†To whom correspondence should be addressed. Tel: +45 3532 1264; Email: jvinther@bio.ku.dk
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
Present address: Søren Iversen, Department of Bacteria, Parasites & Fungi, Statens Serum Institut, 2300 Copenhagen S, Denmark.

© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
ment with the AlkB demethylase and use of TGIRT for reverse transcription therefore improves tRNA profiling and allows global detection of m7A in tRNA (20).

The m7G modification on the Hoogsteen edge does not interfere with reverse transcription, but is specifically sensitive to mild reduction with sodium borohydride (NaBH4), which has been exploited to create abasic sites at m7G modified RNA positions (21,22). After subsequent treatment with aniline, the RNA will be cleaved at the abasic sites, thereby allowing detection by mapping of reverse transcription stops (11,21,22). This strategy forms the basis for the tRNA reduction and cleavage sequencing (TRAC-Seq method), which were used together with an m7G specific antibody based method (m7G McRIP-seq) to confidently map the m7G modifications on mouse tRNAs (12). More recently and while this manuscript was in review, two additional papers describing m7G mapping methods were published (13,23). Both of the studies combined m7G McRIP-seq results with results from methods based on RNA reduction with NaBH4 and biotinylation of abasic sites with biotin reagents. Pandolfini et al. developed a method called Borohydride Reduction sequencing (BoRed-seq) based on pull-down of the biotinylated RNA fragments followed by sequencing and applied it to human miRNAs, which led to the discovery of several human miRNAs with m7G modifications, including Let-7e, which was further characterized (23). Zhang et al. detected m7G modifications at nucleotide resolution by mapping of mutations occurring as a result of misincorporation at the biotinylated sites during reverse transcription and use their methods to map 803 m7G mRNA modifications in human mRNA as well as m7G modifications in human tRNAs (13).

Here, we describe the m7G Mutational Profiling sequencing (m7G-MaP-seq) method for high throughput nucleotide resolution mapping of internal m7G modifications. Our method is based on NaBH4 treatment of RNA and direct detection of mutations resulting from misincorporation at abasic sites during reverse transcription. We show that m7G-MaP-seq detects known and novel m7G modifications in rRNA and tRNA with mutational rates of up to 25%. We find that arabidopsis SSU rRNA has an m7G modification at position 1581, which corresponds to the location of the SSU rRNA position modified both in human and yeast rRNA, suggesting that the SSU m7G modification is universally conserved in eukaryotes. Moreover, by applying m7G-MaP-seq to small RNA sequencing libraries, we detect tRNA m7G modifications from yeast, human and Arabidopsis. In contrast, m7G-MaP-seq analysis of other types of short RNAs and of E. coli and yeast mRNAs failed to identify any internally m7G modified positions.

MATERIALS AND METHODS
Cell culture and RNA isolation
Yeast MATa strain BY4741 (cat. no. YSC1048) were obtained from GE Healthcare Dharmacon (Dharmacon Yeast Knockout collection). The yeast cells were grown at 30° C in YPD medium. At OD = 0.75, the cells were collected by centrifugation, and pellets were washed with ice-cold water and re-suspended in 400 µl ice-cold TES solution (10 mM Tris–HCl pH 7.5, 10 mM EDTA pH 8.0, 0.5% SDS). RNA was extracted using a hot acid phenol protocol.

The E. coli Keio Knockout RsmG strain (OE4987-213607518) and the parental BW25113 strain (OE5042) were obtained from GE Healthcare Dharmacon (E. coli Keio Knockout panel). The strains were inoculated in Luria-Bertani (LB) media (containing 50 µg/ml kanamycin for the knockout strains). Overnight cultures were diluted 1:100 and at OD600 = 0.4, ice-cold EtOH/Phenol stop solution (5% saturated phenol (pH < 7.0) 95% ethanol) was added (6.25 µl per 25 ml cell culture). Cells from 25 ml culture were pelleted at 3000 g for 5 minutes at 4°C and re-suspended in 800 µl TE buffer (100 mM Tris, 10 mM EDTA, pH 8.0) with 0.5 mg/ml lysozyme, followed by the addition of 1/10 vol of 10% Sodium dodecyl sulphate (SDS). After incubation at 64°C for 2 min, 1/10 vol of 1 M NaOAc, pH 5.2 was added, followed by addition of an equal volume of water saturated phenol (pH < 7.0). After incubation at 64°C for 6 min and centrifugation at 14 000 g for 10 min at 4°C, the aqueous layer was transferred to a new tube containing an equal volume of chloroform, inverted repeatedly, and centrifuged at 14 000 g for 5 min at 4°C. The aqueous layer was ethanol precipitated, and the RNA pellet was dissolved in RNase-free water.

Arabidopsis Columbia-0 seeds were washed in 96% ethanol followed by 10% bleach, spread onto solid agar plates and incubated 48 h at 4°C in darkness. Next, the seeds were incubated under light and harvested at day 14. The plant tissue was ground in liquid nitrogen, and 100 mg of the ground tissue was mixed with 1 ml of Trizol (Invitrogen, cat # 15596026), followed by addition of 200 µl chloroform. After vortexing, samples were centrifuged at 14 000 g at 4°C for 10 minutes and 500 µl of the supernatant was mixed with 500 µl isopropanol and incubated at room temperature for 30 minutes. RNA was pelleted by centrifugation at 14 000 g at 4°C for 15 min and washed with twice with 70% ethanol before resuspension in RNase-free water.

HeLa cells were cultured in DMEM medium containing 10% Foetal Bovine Serum, 1% l-glutamate, 1% penicillin/streptomycin. The cells were harvested at ~80% confluency and RNA was isolated using Trizol reagent (Invitrogen, cat. # 15596026) according to the manufacturer’s protocol.

DNase treatment
DNA was depleted from the RNA using the RNase Free DNase Set (Qiagen, cat. # 79254) according to manufacturer’s protocol. The RNA quality was assessed on an Agilent 2100 Bioanalyzer using a RNA pico assay (RIN values were >9).

mRNA enrichment
RNA from yeast were poly(A)-enriched, using the Poly(A) Purist MAG Kit (Ambion, cat. # AM1922), using the standard protocol. The enrichment procedure was performed...
twice. RNA from *E. coli* was rRNA depleted using the Ribo Zero rRNA removal Kit (Illumina, cat. # MRZGN126). Poly-A enriched or rRNA depleted RNA was purified with Agencourt Ampure XP RNAclean beads (Beckman Coulter, cat. # A63987) in a sample:beads ratio of 1:1.2, to reduce the small RNA fraction. The purification was performed according to the manufacturer’s protocol and the purified RNA was eluted in 10 μl RNase-free water.

**Fragmentation**

The RNA was mixed with an equal volume of 2× fragmentation buffer (100 mM Tris–HCl (pH 8), 10 mM MgCl₂), and the samples were incubated at 95°C for 3 min and 20 s. The samples were then placed on ice and EDTA was added to a final concentration of 10 mM. The RNA was purified with Agencourt Ampure XP RNAclean beads (Beckman Coulter) in a sample:beads ratio of 1:3.6, and the purified RNA was eluted in 10 μl of 1 M Tris pH 8.2.

**NaBH₄ reduction**

Fragmented RNA was either incubated with 0.3 M freshly prepared NaBH₄ (NaBH₄ (+) samples) or with RNase-free water (NaBH₄ (−) samples). The pH of the 0.3 M NaBH₄ solution was 9. The reactions were incubated on ice for 30 min in darkness, followed by ethanol precipitation of the RNA, which were used directly for reverse transcription to preserve abasic sites.

**First-strand cDNA synthesis (total RNA and mRNA samples)**

Reverse transcription was performed with the PrimeScript Reverse Transcriptase (Takara Bio) in 35 μl reactions using 10 μl of RNA as template. 100 μM reverse transcription primer (RT_random_primer, see supplementary S1) was added to RNA sample and the mixture was incubated at 65°C for 5 minutes and placed immediately on ice. Next 7.5 μl 5× Primerscript buffer, 7.5 μl 3.3 M/0.6 M sorbitol–trehalose mix, 1.9 μl 10 mM dNTP, 7.6 μl water and 1.5 μl Primerscript reverse transcriptase to each reaction and reverse transcription was carried out at 25°C for 30 s, 30°C for 10 min, 42°C for 30 min, 50°C for 10 min, 56°C for 10 min, 60°C for 10 min. The cDNA was purified with Agencourt Ampure XP beads (Beckman Coulter) in a sample:beads ratio of 1:1.8, and eluted in 35 μl water. The cDNA was then vacuum concentrated to 7 μl.

**3′-end adapter ligation**

Ligation of the adapter to the 3′-end of the cDNA was performed using CircLigase ssDNA Ligase (Epiconcept) in 10 μl reactions. Initially, 3 μl RNA/cDNA duplex were mixed with 0.5 μl 100 μM Ligation_adapter (see supplementary S1) on ice, followed by addition of 6.5 μl master mix consisting of 1 μl CircLigase buffer, 0.5 μl ATP, 0.5 μl MnCl₂, 2 μl 50% PEG 6000, 2 μl betaine and 0.5 μl CircLigase enzyme. Reactions were transferred to a thermocycler and incubated 2 h at 60°C, 1 h at 68°C, and 10 min at 80°C to inactivate the enzyme. The cDNA was purified with Agencourt Ampure XP beads (Beckman Coulter) in a sample:beads ratio of 1:1.8, and the purified cDNA was eluted in 10 μl water.

**Library amplification by PCR**

The amplification of the library was conducted using Phusion® High-Fidelity DNA Polymerase (New England Biolabs, Cat #m0530) and custom Illumina-compatible primers (see supplementary S1). Reactions of 50 μl were prepared and consisted of 7 μl single stranded cDNA, 3 μl forward primer, 2.5 μl reverse index primer, 10 μl Phusion 5× HF buffer, 4 μl 2.5 mM dNTPs, 22.5 μl water and 1 μl Phusion Polymerase.

The reactions were denatured for 3 min at 98°C, followed by 4 cycles of 98°C for 80 s, 64°C for 15 s and 72°C for 1 min followed by 14–17 cycles of 98°C for 80 s and 72°C for 1 min and subsequently 72°C for 5 min. The samples were pooled and run on the E-Gel® iBase™ Power System (Thermo Fisher) with the ‘SizeSelect 2%’ program to remove primer-adapter contamination. Following collection of the 150–600 bp fraction, the pooled library was ethanol precipitated, and sequenced on the Illumina NextSeq platform.

**Small RNA library preparation**

Total RNA (1 μg) with a RIN value of 9.8 or higher was either NaBH₄ or mock treated as described in the ‘NaBH₄ reduction’ section. Small RNA libraries of yeast, human and arabisopsis were prepared using ‘The NEBNext Multiplex Small RNA’ kit according to manufacturer’s protocol. The pooled libraries were run on the E-Gel® iBase™ Power System (Thermo Fisher) with the ‘SizeSelect 2%’ program to remove 5.8s rRNA and to selectively exclude the >250 bp fraction. The pooled libraries were ethanol precipitated and sequenced on the Illumina NextSeq platform.

**SSU rRNA sub-fragment isolation and mass spectrometry analysis**

An ~50 nucleotide fragment of the *A. thaliana* SSU rRNA sequence around G1581 was isolated for MALDI Time-of-Flight mass spectrometric analysis. Purified total RNA was hybridized with a complementary oligodeoxynucleotide Ara_LSU_1581 (Supplementary Table S1), followed by digestion with mung bean nuclease and RNase A as described in (24). After sub-fragment purification on a denaturing polyacrylamide gel, the RNA was separately digested with RNase A (pyrimidine-specific) for mass spectrometric analysis as previously reported (25). Briefly, 1–2 pmol RNA sub-fragment were RNase A digested to completion and analysed using 3-hydroxypropionic acid as matrix. Mass spectra were recorded in positive ion mode with a reflectron Time-of-Flight mass analyzer on a Bruker UltraFlex MALDI instrument and processed using the software ‘m/z’ (Proteometrics). The observed digestion pattern was compared to a theoretical ditto calculated using
GPMAW software (Lighthouse Data, Denmark). Tandem mass spectrometry to investigate exact positions of the observed modifications was performed on a Waters Q-TOF Premiere instrument (Waters, Manchester, UK) equipped with a MALDI ion source in positive ion mode as previously described (26).

Reads pre-processing and mapping

All raw data files and the fines processed data files containing the data used for making figures are available at GEO under accession GSE121927. The analysis is described in detail at https://github.com/jeppevinther/m7g_map_seq. In brief, sequencing reads from regular RNA-Seq experiments were processed with Cutadapt to remove adapter sequences and trim dark cycle artefacts from the two colour Nextseq platform using the options -a AGATCGGAAGAGCAGCAGTCT -nnextseq-trim = 20. The preprocessing.sh script from RNAProbR package (27) (http://people.binf.ku.dk/~jvinther/data/rna_probing/) was used to remove the 7 base barcode from the sequencing read using the options '-b NNNNNNNN -t 9' and the barcode information was saved in a separate file. Reads having one or more Ns in the barcode sequence were discarded before mapping with bowtie2 using high sensitivity options '-local -N1 -D20 -R3 -L15'.

For analysis of ribosomal rRNA, reads were mapped to ribosomal sequences obtained from the CRW database (28). For E. coli mRNA analysis, reads were mapped to the ensembl cDNA release 87 for the bw25113 strain ftp://ftpensemblgenomes.org/pub/release-29/bacteria/fasta/bacteria_87_collection/escherichia_coli_bw25113.cdna/Escherichia_coli_bw25113.GCA_000750555.1.29.cdna.all.fa.gz. For yeast mRNA analysis, reads were mapped to the ensembl cDNA release 84 of S. cerevisiae ftp://ftpensemblgenomes.org/pub/release-84/fasta/saccharomyces_cerevisiae/cdna/Saccharomyces_cerevisiae.R64-1-1.cdna.all.fa.gz. Potential PCR duplicates among the sequencing reads were removed by discarding all, but one of the reads having identical barcode and mapping to the same position using the collapse.sh script (http://people.binf.ku.dk/~jvinther/data/RNA-seq/).

Sequencing reads from small RNA-Seq experiments were processed and mapped using the settings described above but as these reads do not include the adapter barcode, no pre-processing and collapsing of PCR duplicates on barcodes were performed. For tRNA analysis of yeast, human and arabidopsis, reads were mapped to the high confidence tRNA fasta sequences obtained from the genomic tRNA database (http://grtrnadb.ucsc.edu/index.html). Prior to mapping, redundant/identical RNA sequences from different genes were collapsed, tRNA introns were removed from the sequences and 3' terminal CCA were added. For histidine tRNAs a 5' G were added to the sequence. In the analysis of unspliced tRNA, both the spliced and unspliced tRNA sequences were included in the fasta sequence used for mapping. For the analysis of Arabidopsis and human miRNAs, reads were mapped to the miRbase miRNA precursor annotation ftp://mirbase.org/pub/mirbase/CURRENT/hairpin.fa.gz. Sequences for other sRNA were obtained using BioMart from the Ensembl human gene (GRCh38.p12) annotation with a filter restricting to genes annotated as ‘scRNA, scRNA, snoRNA, snRNA, sRNA’ and Arabidopsis thaliana gene (TAIR10) annotation with a filter restricting to genes annotated as ‘snRNA, snRNA, SRP, RNA’.

Detection of mutations and statistical analysis

The mapped reads for the control and NaBH₄ treated samples were processed with the mpileup tool from the samtools package using per-Base Alignment Quality, which estimates the probability of a read base being wrongly aligned (29,30). To parse the mpileup output into tabular form and perform statistical analysis, we developed an R-script (getFreq2000.R) based on the statistical principles developed in the ANGSD package (31). The statistics employed in the analysis is described in the Supplementary methods and the getFreq2000.R script is available at https://github.com/jeppevinther/m7g_map_seq. Briefly, the R function takes a samtools mpileup output file as input and outputs a number of statistics for each position, including the sequencing depth, the estimated mutation frequency for the treated and control samples taking the probability of a read base being wrongly aligned into account. The mutation rate difference used for testing in most of our figures is the estimated mutation frequency for the control subtracted from estimated mutation frequency for the treated sample. In addition, the script uses log likelihood tests to calculate P-values for the estimated mutation rates being different in the treated and control samples. Likewise, it also tests for difference mutation rates within the replicate samples. For a full description of the output of the R script, see Supplementary Table S2.

Data analysis

The output from the getFreq function was used for plotting and further data analysis in R. For the rRNA analysis, only positions having a sequencing depth higher than 500 was used. For the tRNA and mRNA analysis, only positions having a combined sequencing depth higher than 1500 in the six samples, an average mutation frequency less than 1% in the control replicates, and no significant difference in mutation rates (P-value < 10⁻⁵) within control or NaBH₄ treated replicates were used for preparing figures. The Modomics database (10) was used for annotation of tRNA m⁷G, m⁵A and dihydouridine positions.

RESULTS

m⁷G-MaP-seq detects m⁷G modifications

In m⁷G-MaP-seq, we exploit the specific sensitivity of m⁷G to mild reduction with sodium borohydride (NaBH₄), which lead to formation of RNA abasic sites (Figure 1A). In contrast to previous methods, we preserve the abasic sites in the RNA and use reverse transcription with the Prime-script MMLV reverse transcriptase to record the positions of m⁷G modifications directly as mutations in the cDNA primary sequence (Figure 1A and Supplementary Figure S1). The cDNA is used to prepare libraries for massive parallel sequencing and the resulting data is mapped to a relevant reference using local alignments and high sensitivity settings. To perform data analysis and detect positions
Figure 1. (A) Schematic representation of the m7G-MaP-Seq method. NaBH4 treatment leads to formation of abasic sites at m7G positions, which subsequently are converted into cDNA mutations during reverse transcription and detected by massive parallel sequencing. (B) Detection of m7G at E. coli SSU rRNA position 527 and E. coli LSU rRNA position 2069 in WT strain. (C) Detection of m7G at E. coli SSU rRNA position 527 and E. coli LSU rRNA position 2069 in RsmG knockout strain. (D) Boxplots showing consistent detection of m7G modified positions in biological replicates.
with increased mutation rates in the reduced samples compared to control samples, we developed a pipeline based on the mpileup tool from the samtools package (29,30) and a new tool called getFreq, which we developed based on the ANGSD package (31). Our new tool takes the observed sequence bases and the possibility of sequencing/alignment error into account to calculate estimated mutation rates for the treated and control samples, which are subtracted to give a mutation rate difference for each position. Moreover, our tool uses replicates samples to calculate the statistical significance of the mutation rate difference based on log likelihood ratio tests and several other statistics (See Supplementary Table S2 and the Supplementary Methods). To validate the method, we first applied m^7G-MaP-Seq to E. coli rRNA, where two m^7G modifications are known. One is located in the conserved 530 loop of hairpin 18 in the bacterial SSU rRNA (m^7G527 in E. coli) (7) and the other at position 2069 within the peptidyl transferase center of LSU rRNA (6). NaNBH_4 treatment specifically induced deletions and misincorporations at the two known m^7G modified positions and resulted in mutation rate differences of 10% and 5% (Figure 1B), respectively. To demonstrate that our method specifically detects the m^7G modifications and not some other feature of positions 527 and 2069, we repeated the experiment using a knockout strain for the RsmG methyltransferase known to carry out the modification at position 527 (7). As expected, we found that the knockout specifically eliminated NaNBH_4 treatment induced mutations at position 527, while the normalised mutation rate of any other position remained unaffected (Figure 1C). Next, we applied m^7G-MaP-Seq on three biological replicates and found that the observed mutation rate differences for each position were highly reproducible between the replicates within the experiment (Figure 1D), whereas we observe some variation in the mutation rates obtained between different experiments (compare Figure 1B with 1D).

To analyse the relationship between the modification frequency and the observed mutation rates, we first established that the E. coli SSU product G1578-U1584, m/z 2375.42—and a spontaneous truncation of this, G1578-A1582, m/z 1722.28—close to 100% modified (Figure 2B). Tandem mass spectrometry was applied to pinpoint the methylation in G1578-U1584 (Supplementary Figure S4) and G1578-A1582 (data not shown), where the two methyl groups were assigned to A1579 and G1581, respectively. The loss of a methylated G base (m/z 2210.35) shows that the methylation of position 1581 is on the guanine. This demonstrates that the SSU G1581 methylation is conserved in araboids (Figure 2C).

m^7G-MaP-Seq detects known and novel m^7G modifications in rRNA

Next, we applied m^7G-MaP-Seq to total RNA isolated from yeast (S. cerevisiae), araboids (A. thaliana) and human (H. sapiens) cells in a single replicate. For both human and yeast rRNA, we detected the known small subunit (LSU) rRNA m^7G modification at positions G1639 and G1575, respectively (Figure 2). In araboids SSU rRNA, no m^7G methylation equivalent to the G1575 methylation in yeast has been described, but m^7G-MaP-Seq detects an m^7G modification at position G1581, which aligns to the yeast SSU rRNA G1575 (Figure 2C). To further validate the araboids m^7G methylation at SSU G1581, we purified an RNA fragment surrounding the position and subjected it to RNase A digestion and Matrix-Assisted Laser Desorption/Ionization mass spectrometry (MALDI-MS) and tandem mass spectrometry. The mass spectrometry analysis demonstrates two methylations in the RNase A product G1578-U1584, m/z 2375.42—and a spontaneous truncation of this, G1578-A1582, m/z 1722.28—close to 100% modified (Figure 2B). Tandem mass spectrometry was applied to pinpoint the methylation in G1578-U1584 (Supplementary Figure S4) and G1578-A1582 (data not shown), where the two methyl groups were assigned to A1579 and G1581, respectively. The loss of a methylated G base (m/z 2210.35) shows that the methylation of position 1581 is on the guanine. This demonstrates that the SSU G1581 methylation is conserved in araboids (Figure 2C).

m^7G-MaP-Seq maps m^7G modifications in tRNA

A subset of tRNAs are m^7G modified at position 46 in the variable loop and for yeast tRNAs, the m^7G modifications have been annotated (10). We applied m^7G-MaP-Seq to small RNA isolated from yeast in biological triplicates with one treated and one control library per replicate. For tRNAs, we mapped to sequence files containing all known tRNA isodecoders and used high sensitivity mapping settings, which allows distinction of tRNA isodecoders differing in as little as one sequence position. When sequencing reads cover both the potential m^7G modification at position 46 and the positions that differ between isodecoders, our analysis has the potential to detect isodecoder specific m^7G modifications. The analysis was limited to tRNA positions with a sequencing depth of more than 1500 in the six samples combined, an average mutation frequency <1% in the control replicates, and no significant difference in mutation rates within replicates (see Methods for details). Some tRNAs, such as Ile-TAT-2, Pro-AGG-1 and Thr-TGT-2 showed highly significant mutation rate differences specifically at position 46, whereas others, such as tRNA-Gly-TCC-1 did not (Figure 3A).

To detect m^7G modification on a global scale, we plotted the observed difference in mutation rate versus the P-value obtained for the comparison of the control samples with the NaNBH_4 treated samples for all positions (Figure 3B). Using a cut-off of 0.5% for the mutation rate difference and P-value threshold 10^-50 for the difference between rates, we specifically predict all but three of the m^7Gs annotated in the Modomics database for yeast tRNAs as having
m^7G modifications (Figure 3B) (10). The three tRNA for which no m^7G modification is detected are Met-CAU, Lys-UUU and Cys-GCA and they all have increased relative frequency and a P-value < 10^-10 but does not reach our strict cut-off (Figure 3B). For two tRNAs (tRNA-Pro-AGG and tRNA-Thr-TGT) not previously known to be m^7G modified, the m^7G-MaP-seq data predict that position G46 is indeed modified (Figure 3C, Supplementary Table S3). Moreover, the m^7G-MaP-seq analysis also shows that several tRNAs with G in position 46 do not show any signs of modification (Ala-AGC-1, Ala-TGC-1, Leu-GAG-1, Leu-TAA-1, Leu-TAG-1, Ser-AGA-1 and Ser-AGA-2, Ser-GCT-1).

In addition to m^7G positions, some positions known to be N1-methyladenosine (m1A) and Dihydrouridine (D) modified also pass our filter and have increased relative mutation frequency and low P-values (Figure 3B). Dihydrouridine positions are known to be susceptible to NaBH4 reduction, potentially leading to the formation of abasic sites (32). For known m1A positions, we consistently find increased mutation rates in the NaBH4 treated samples, suggesting that m1A is susceptible to mild reduction with NaBH4 (Supplementary Figure S5).

A subset of yeast tRNAs undergoes splicing and it is not known whether these tRNAs are m^7G modified before or after splicing takes place. We therefore compared the m^7G-MaP-Seq signal from the reads mapping to the unspliced and the mature tRNA, respectively. As previously demonstrated for tRNA m^1A modifications, we find that the unspliced yeast tRNA molecules are m^7G modified on position 46 prior to splicing, suggesting that m^7G modification take place early in tRNA maturation (Supplementary Figure S6). Next, we applied m^7G-MaP-Seq to small RNA isolated from human HeLa cells and arabidopsis (Figure 4).

Human and arabidopsis tRNAs have more RT-terminating modifications such as m^1A, N3-methylcytidine (m^3C) and N1-methylguanosine (m^1G) and N2,N2-dimethylguanosine (m^22G), resulting in relatively fewer tRNAs having sufficient sequencing depth for analysis. Nevertheless, among the tRNAs expressed in HeLa cells, m^7G-MaP-seq identifies eight different tRNA isodecoder families modified at position 46 (Figure 3D), for all of which the homologous mouse tRNA were previously found to be m^7G modified by the TRAC-seq method (12). For tRNA-Val-CAC, we find that isodecoders 1, 2 and 3 are all m^7G modified on position 46, whereas the isodecoder 11 did not show any evidence of modification in m^7G-MaP-seq.

There is no available annotation of m^7G tRNA modifications in arabidopsis and we therefore applied m^7G-MaP-seq to small RNA purified from arabidopsis 14-day old seedlings (Figure 3E). Based on the analysis, we predict that Arg−ACG, Asn−GTT, Asp−GTC Met−CAT, Pro−TGG, Thr−TGT, Trp−CCA−3, Thr−GGT and Thr−TGT are m^7G modified, whereas Arg−TCT, Gln−TTC and Leu−TAG are not modified.

No evidence for m^7G modifications in human miRNAs, including human Let-7e

Kouzarides and colleagues recently reported m^7G modifications within a subset of human miRNAs, including Let-7e, for which the m^7G modification was validated and localized to position 18 using mass spectroscopy of a RNaseA fragment of the miRNA (Figure 4A) (23). While the application of m^7G-MaP-seq to human small RNAs mapped known tRNA m^7G modifications with high confidence (see Figure
Figure 3. (A) Sequencing depth and m7G-MaP-seq $-10\log_{10}(p\text{-val})$ for selected yeast tRNA. (B) Mutation rate difference versus $-10\log_{10}(P\text{-val})$ plot of all detected yeast tRNA positions. Known m7G positions are specifically detected by m7G-MaP-seq. (C) m7G-MaP-seq $-10\log_{10}(p\text{-val})$ for yeast tRNA positions aligning to position 46 in the tRNA variable loop. (D) Mutation rate difference vs $-10\log(p\text{-val})$ plot of all detected human tRNA positions. (E) Mutation rate difference vs $-10\log_{10}(p\text{-val})$ plot of all detected Arabidopsis tRNA positions.
Figure 4. (A) Sequences of the Human Let-7e precursor and human LSU rRNA 4333-4345. Identical RNase A fragments are indicated as well as the Let-7e position reported by Pandorfini et al. to be m7G modified and the corresponding 2′ OMe G4340 position known to be modified in LSU rRNA and guided by snoRNA U60 (Krogh et al.). (B) Mutation rate difference versus −10*log(P-val) plot for 1239 Gs in 175 different human miRNAs. (C) Coverage and P-values obtained for the Human Let-7e precursor sequence. Position 18 is indicated. (D) Analysis of the power to detect m7G modification at position 18 in the human Let-7e. The curves show the power for 4 different detection levels of m7G modifications with the sequencing depth observed for Let-7e.

3), we find no evidence of m7G modifications in any human miRNA (Figure 4B). For Let-7e, we have very high sequencing depth (Figure 4B) but we do not observe any mutations in the treated samples for this position. In this specific experiment, tRNAs m7G positions are detected with mutational rates in the range of 0.5% to 6% (Figure 3D). If we conservatively assume that the m7G modification on Let-7e would also be detected with a 1% mutation rate if 100% modified, then we estimate that we would have 100% power to detect the Let-7e modification with a P-value better than 10−5 if 10% of Let-7e molecules were m7G modified (Figure 4C). The fact that we do not observe any mutations for Let-7e position 18 demonstrates that for the HeLa cells used in our study, this position is not m7G modified at a biologically relevant level.

No evidence for m7G modifications in yeast and E. coli mRNAs

In human mRNAs, 803 m7G modified positions were recently reported, suggesting that mRNA in other species may also be m7G modified. We applied m7G-MaP-seq to mRNA from E. coli and yeast in biological triplicates. In our analysis, 193590 E. coli mRNA (Figure 5A) and 377837 yeast mRNA G positions (Figure 5B) had a sequencing depth of more than 1500 in the three control and three treated replicates combined, an average mutation frequency <1% in the control replicates, and no significant difference in mutation rates within replicates (see Materials and Methods for details). This corresponds to approximately 20% and 16% of the G content of the entire transcriptome of E. coli and yeast, respectively. However, in neither of the two analy-
Figure 5. (A) Mutation rate difference versus \(-10\log_{10}(P\text{-val})\) plot for *E. coli* mRNA G positions \((n = 193\,590)\) and *E. coli* rRNA G positions. The two known *E. coli* ribosomal m7G modifications are indicated. (B) Mutation rate difference versus \(-10\log_{10}(P\text{-val})\) plot for yeast mRNA positions \((n = 377\,837)\). The known yeast ribosomal m7G modification at 1575 is indicated.

Figures

The two known *E. coli* ribosomal m7G modifications are indicated. (B) Mutation rate difference versus \(-10\log_{10}(P\text{-val})\) plot for yeast mRNA positions \((n = 377\,837)\). The known yeast ribosomal m7G modification at 1575 is indicated.

**DISCUSSION**

In this paper, we present m7G Mutational Profiling sequencing (m7G-MaP-seq), which allows sensitive and high throughput detection of internal m7G modifications in any type of RNA. Mutational profiling has previously been applied to obtain nucleotide resolution mapping of RNA-protein interactions, m1A modifications and for Selective 2-hydroxyl acylation analysed by primer extension (SHAPE) based probing of RNA structure, and here we demonstrate that this strategy also can be successfully applied to detect internal m7G modifications. Our method is based on the treatment of RNA with NaBH4, leading to the formation of abasic sites at m7G positions. Abasic sites in RNA are relatively stable, and during the subsequent reverse transcription m7G positions are permanently recorded as mutations in the cDNA sequence. m7G-MaP-seq can be implemented in any sequencing protocol, including regular RNA-seq experiments, and small RNA-seq by addition of NaBH4 treated samples in the experimental setup and application of our pipeline for data analysis. Compared to methods based on the mapping of reverse transcription stops, mutational profiling makes better use of the sequencing reads and has improved sensitivity because bias from RNA fragmentation, adapter ligation and secondary structures is reduced. In global RNA modification mapping experiments, it becomes very important to establish the background detection rates and account for these when modifications are mapped (33). We developed a pipeline that incorporates re-estimated base qualities, which are used to provide estimated mutation frequencies using an EM-algorithm. In addition, our tool applies log likelihood ratio tests to obtain *P*-values for differences in mutation rates both within replicates and between the control and NaBH4 treated samples, making m7G-MaP-seq highly suitable for global analyses.

Apart from m7G, we also find that NaBH4 treatment induces increased mutation rates of N4-acetylcytidine (ac4C), dihydrouridine (D) and m1A. This is in agreement with a recent publication using NaBH4 treatment for detection of ac4C (34) and the known susceptibility of D for cleavage of the dihydrouridine ring upon reduction by NaBH4 (32). In contrast, for m1A positions NaBH4 treatment was not expected to lead to increased mutation rates. Rather, the alkaline conditions during reduction could potentially lead to Dimroth rearrangement to m6A and thereby decrease mutation rates, as previously used to improve m1A signal in global sequencing-based mapping experiments (15). Typically, the Dimroth rearrangement is performed at elevated temperatures (35), whereas we here perform NaBH4 treatment on ice, which likely explains that we do not observe widespread rearrangement to m6A and decreased mutation rates. NaBH4 treatment of m1A results in the formation of 1-methyl-6-hydroadenosine, which is fairly stable, but can be re-oxidized to m6A (35). The reduction to 1-methyl-6-hydroadenosine results in the loss of planar conformation and aromatic character of the six-membered ring. Our results suggest that 1-methyl-6-hydroadenosine is relatively stable under our conditions and that A is relatively efficiently incorporated into cDNA during reverse transcription at 1-methyl-6-hydroadenosine positions (Supplementary Figure S5B).

We find that different m7G positions have variation in their m7G-MaP-seq mutational rates, which may be the result of differences in the level of m7G modification, but probably also reflects that the local sequence influences the efficiency of abasic sites formation during reduction and of reverse transcriptase abasic site read-through. In this study, we successfully use MMLV based reverse transcriptases Primerscript (total RNA and mRNA libraries) and Protoscript II (small RNA libraries) for m7G-MaP-seq, however, the use of thermostable group II intron reverse transcriptase (TGIRT) could potentially allow higher read-through rates.
and thereby increase the signal. Another possibility could be inclusion of Mn$^{2+}$ in the reverse transcription buffer, which in SHAPE-MaP-seq has been shown to increase RT read-through rates of 2′ acetylated RNA positions (36). While the study was under review, He et al. published the m$^3$G-seq method, which also use mutation mapping for detection of m$^3$G modifications. Compared to our method m$^3$G-seq includes an additional step to biotinylate the basic sites, which allows subsequent enrichment of the RNA fragments. For this reason, m$^3$G-seq will probably be better to identify low frequency m$^3$G modification than m$^3$G-MaP-seq. In future applications of m$^3$G-MaP-seq, we plan to combine our protocol with m$^3$G specific antibody immunoprecipitation of RNA fragment (12,13,23) before the NaBH$_4$ treatment, which potentially would facilitate the detection of positions with low frequency m$^3$G modifications.

We demonstrate that m$^3$G-MaP-seq detects known and novel m$^3$G modifications in rRNA and tRNA. In human SSU rRNA, we detect the modification of position 1639, which has previously been shown to be m$^3$G modified by WBSCR22-TRMT112 (4,5). This modification is conserved to yeast SSU position G1575 and here we show that the arbidopsis SSU rRNA is also modified at the homologous position G1581 (Figure 2C), suggesting that SSU m$^3$G methylation is conserved between eukaryotes and that arbidopsis Bud23 homolog RID2 is a functional m$^3$G methyltransferase (37). In contrast, we did not observe any signal at position 1605, 2522 and 4550 in human LSU rRNA, which were recently reported to be m$^3$G modified based on a high resolution cryoEM structure of the human 80S ribosome (38). As in our study, the cryoEM study is based on rRNA purified from HeLa cells, suggesting that the inconsistent results are not cell type related. Our data, together with mass spectroscopy based analysis of human LSU rRNA from the Isobe group (39), therefore strongly suggests that m$^3$G modifications are not reliably detected from current cryoEM data, which is furthermore supported by the fact that the cryoEM study did not detect the well-known m$^3$G modification on SSU position 1639 (38).

We also applied m$^3$G-MaP-seq to small RNA purified from yeast, arbidopsis and human cells. In these experiments, we observe m$^3$G modifications on tRNAs only, for which a subset is known to be m$^3$G modified at position 46 in the variable loop, whereas no other sRNA was found to be modified (Supplementary Figure S7). tRNA modifications have been most extensively annotated in yeast and with m$^3$G-MaP-seq we validate nine out of twelve tRNA previously known to have m$^3$G modifications in yeast. In addition, we demonstrate m$^3$G modifications on tRNA-Pro-AGG and tRNA-Thr-TGT, which were not previously known to be m$^3$G modified. Our results are in agreement with existing mapping of yeast m$^3$G modifications, including tRNAs previously found not to be m$^3$G modified (Supplementary Table S3) (11). By specifically analyzing the reads containing tRNA introns, we find that for tRNA m$^3$G modifications occur early, before the tRNA intron has been spliced out (Supplementary Figure S6), similar to what was previously shown for m$^3$A modifications (20). Among human tRNAs, we identify m$^3$G modifications on 8 different isodecoder families (Figure 4). Gregory and colleagues previously published the TRAC-seq method and applied it to small RNA from mouse embryonic stem cells (12). Their study implemented AlkB treatment to increase sequencing depth of tRNA carrying modifications that terminate reverse transcription and convincingly identified the entire subset of mouse tRNA that are m$^3$G modified. Likewise, He and colleagues applied their m$^3$G-seq method to detect m$^3$G modifications human tRNA. Our results on human tRNA agree with the TRAC-seq and m$^3$G-seq data, but we have sufficient sequencing depth on much fewer RNAs. Interestingly, our m$^3$G-MaP-seq data shows that human tRNA-Val-CAC-1 is not m$^3$G modified, whereas tRNA-Val-CAC-1, 2, 3 and 4 are all predicted to be m$^3$G modified, although all these Val-CAC isodecoders have exactly the same variable loop sequence. However, Val-CAC-11 has a destabilized T-arm with one mismatch and three G-U wobble basepairs, which may explain the lack of modification as the T-arm was previously shown to be required for m$^3$G modification of yeast tRNA-Phe by purified Trm8–Trm82 heterodimer (40). These results show the potential of m$^3$G-MaP-seq to distinguish tRNA isodecoders and determine their m$^3$G modification status. For arbidopsis tRNAs, we provide a preliminary annotation of m$^3$G modifications, where 9 tRNAs were predicted to be modified. Future implementation of AlkB treatment and/or TGIRT in the m$^3$G-MaP-seq protocol should facilitate a complete annotation of m$^3$G tRNA modifications in arbidopsis and for most other species for which no m$^3$G modification annotation exists.

In a recent publication by Pandolfini et al., it was reported that a subset of human miRNAs are m$^3$G modified, including Let-7e, for which the m$^3$G modification was validated and localized to position 18 using mass spectroscopy of a RNase A fragment of the gel purified miRNA fraction (Figure 5A) (23). In HeLa cells, we demonstrate that Let-7e position is not m$^3$G modified and we note that the sequence of the Let-7e RNase A fragment analysed by Pandolfini et al. is identical to the human LSU rRNA 4336–4342 RNase A fragment (Figure 5A). The LSU rRNA 4336–4342 fragment has previously been analysed with mass spectroscopy and was shown to be 2′ OMe modified on position 4340 (39), which is in agreement with results from sequencing-based 2′ OMe mapping experiments on human ribosomal RNA (41). LSU rRNA position 4340 and Let-7e position 18 are both is position 5 in the RNase A fragments (Figure 5A), meaning that the mass spectra obtained by Pandolfini and colleagues for Let-7e m$^3$G modification potentially could be derived from RNA contamination of the miRNA fraction. Alternatively, the A549 cells used in their study may have more abundant miRNA m$^3$G modifications than the HeLa cells used in our study.

Zhang et al. used mass spectroscopy on purified and de-capped mRNA fractions from different human mouse cell types and found that the mRNAs contained from 0.02 to 0.05% m$^3$G when compared to the amount of G (13). They also used m$^3$G-seq to detect 803 human mRNA internal m$^3$G modifications that were detected in both HeLa and HepG2 cells. We applied m$^3$G-MaP-seq to mRNAs purified from E. coli and S. cerevisiae cells and did not identify any m$^3$G modified internal mRNA positions, whereas we in the same experiment detect the known ribosomal m$^3$G modifications with high significance (Figure 5). For both species,
our analysis has high sequencing depth on a substantial fraction of Gs in the transcriptome, 20 and 16 percent, for *E. coli* and *S. cerevisiae*, respectively. We estimate that the cut-off sequencing depth of 750 reads per group (1500 in total) gives us around 90% power to detect a m^7G modification present at a frequency of 0.2, whereas a sequencing depth of 3000 reads per group gives 90% power to detect a modification present at a frequency of 0.05 (Supplementary Figure S8). We therefore demonstrate that medium/high frequency internal m^7G modifications are not widespread in *E. coli* and *S. cerevisiae* mRNA. Future application of m^7G-seq or m^7G-MaP-seq with higher sequencing depth and potentially combined with antibody-mediated m^7G pull-down will allow detection of potential low frequency m^7G modifications in highly expressed mRNA and high frequency m^7G modifications in lowly expressed mRNA.

In conclusion, we have developed the m^7G-MaP-seq method, which allows high throughput detection of m^7G RNA modifications. The method can be implemented with existing RNA-sequencing protocols and we provide an efficient computational pipeline for data analysis. In this study, we identify known and novel m^7G modifications in rRNA and tRNA and find that the human Let-7e is not m^7G modified in HeLa cells. We expect that the m^7G-MaP-seq method will facilitate future studies on internal m^7G RNA modifications.

**SUPPLEMENTARY DATA**

**Supplementary Data** are available at NAR Online.

**ACKNOWLEDGEMENTS**

The authors would like to thank Amal Al-Chaer and Lena Bjorn Johansson for technical assistance and Axel Thieffy for help with Arabidopsis RNA purification.

**FUNDING**

Danish Council for Strategic Research (Center for Computational and Applied Transcriptomics) [DSF-10-092320]; Novo Nordisk Foundation [NNF16OC0021712]. Funding for open access charge: Department of Biology, University of Copenhagen.

**Conflict of interest statement.** None declared.

**REFERENCES**


